News

An action filed in U.S. District Court for the Northern District of Illinois by a Pennsylvania woman alleges that neither she nor her physicians were alerted that Tepezza could result in loss of hearing or tinnitus. Horizon said in a statement this and other lawsuits are without merit.

AVA-Net is a deep-learning network developed by scientists from the University of Illinois at Chicago.

The Centre for Ocular Research and Education is demonstrating its latest discoveries for eye applications at the Association for Research in Vision and Ophthalmology’s annual meeting in New Orleans.

The company said this week it plans to open the trial for enrollment this quarter and expects topline results by the third quarter of 2024.

Reducing treatment burden, finding something other than a shot a month is key.

During a presentation at the Vit-Buckle Society meeting in Las Vegas, Sally S. Ong, MD, highlighted a new study of patients who underwent primary repair of uncomplicated RRDs at the Wilmer Eye Institute to examine the baseline, surgical and postoperative characteristics that affect best-corrected VA outcomes.

The GA Won’t Wait campaign is designed to help older adults and their families understand and recognize the symptoms of this progressive and irreversible disease.

As technology advances, innovations increase physician capabilities.

Physician outlines the latest emerging technologies to treat the condition.

A large cohort study found that there is no association between the first mRNA COVID-19 vaccinations and acute RVO.

Vance Thompson, MD, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss his presentation at the Real World Ophthalmology meeting on Pearls for cataract surgery.

The technology could prove to be the foundation for establishing a new biomarker of ocular diseases.

Jennifer Lim, MD, FARVO sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss her presentation at this year's Vit-Buckle Society meeting on keratoprosthesis combined with vitrectomy surgery.

Daraius Shroff, MD, developed the Triple S toolkit for hAM grafting for use during vitreoretinal surgery, which he described at the 2023 Vit-Buckle Annual Society meeting.

J. Peter Campbell, MD, MPH, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss pediatric retina surgery and 3 key pearls to consider while performing the surgery.

According to the company, intermediate dry AMD Treatment Is a significant unmet need, with mitochondrial stabilizing candidate risuteganib demonstrating BCVA gains in the dry AMD patient population.

The device is an update on the previous iTrack canaloplasty device and features an ergonomic handpiece.

The clearance of the Investigational New Drug Application will allow the company to initiate Phase 2 trials of the drug for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

SeeLuma is a “Fully Digital Surgical Visualization Platform” to assist ophthalmic surgeons.

According to the company, KPI-012 could become the first approved treatment for persistent corneal epithelial defect across all its various etiologies.

The study compared eyes with retinopathy of prematurity (ROP) that were treated with laser and age-matched control eyes without ROP.

Esen Akpek, MD, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss ocular surface disease and the lifestyle choices that could affect eye health. As well as what The Tear Film & Ocular Surface Society is doing to promote research on the topic.

A research team made up of scientists from a trio of European universities and led by a Northumbria University academic, has received funding to research age-related macular degeneration.

Patients and employees, past and present, have had personal and protected health information acquired without authorization.

If no comment from the FDA is received within 30 days, the company said it will initiate the BRM424 phase 2 study in the first half of 2023.

According to data, 62% of patients treated with teprotumumab-trbw had a clinically meaningful improvement in proptosis at Week 24compared with 25% of patients receiving placebo.

The ESSENCE-2 study showed a significantly greater reduction in the total corneal fluorescein staining (tCFS) score.